Recombinant Dna Technology Market, By Product Type (Recombinant Protein Drugs, Vaccines , Genetically Modified Crops, Cell and Gene Therapy, and Gene Editing), By Application (Therapeutics, Agriculture, Research, and Others), By End User (Biotechnology and Pharmaceutical Company, Diagnostic Laboratories, Academic and Government Institutes, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025

Code : CMI893

Pages :183

Formats :

Excel and PDF

Industry : Biotechnology

Recombinant Dna Technology Market Size and Trends

The recombinant DNA technology market is estimated to be valued at USD 189.91 Bn in 2025 and is expected to reach USD 365.62 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2025 to 2032.

Recombinant Dna Technology Market Key Factors

To learn more about this report, Request sample copy

The recombinant DNA technology market is expected to witness rapid growth during the forecast period owing to increasing investments in research and development activities by pharmaceutical and biotech companies. With rising demand for protein therapeutics and monoclonal antibodies, the demand for recombinant DNA technology is also rising. Continuous advancements in genetic engineering tools and genomic analysis are further expected to drive the market growth. Adoption of recombinant proteins in healthcare and increasing availability of recombinant vaccines and hormones are some key factors propelling the market growth.

Increasing Technological Advancements are Facilitating the Production of Novel Products

Tremendous advancements combined with a wide range of applications of recombinant DNA technology to treat life-threatening human diseases such as cancer, diabetes, and infectious diseases are expected to be the major factors augmenting the market growth. According to the Global Diabetes Community, in 2021, an estimated 537 million adults are suffering from diabetes worldwide, and the number is expected to escalate to 643 million by 2030. Moreover, in February 2021, according to the World Health Organization (WHO), an estimated 6.7 million deaths were directly caused by diabetes and 2.2 million deaths were attributable to hyperglycemia or high blood glucose levels. Advancements in recombinant technologies have facilitated the development of long-acting therapeutic proteins for drug development as well as introduced gene therapy, which is a novel molecular medicine, thus supporting the growth of the recombinant DNA technology market by creating a positive impact on the treatment of genetic diseases. Moreover, the novel gene-editing tool – Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), can be used to target the destruction of abnormal genes in human cells, and it has provided scientists a powerful way to make precise changes to DNA of microbes, plants, mice, dogs, and human cells.